272 related articles for article (PubMed ID: 32220885)
21. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
[TBL] [Abstract][Full Text] [Related]
22. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing.
Malouf GG; Zhang J; Yuan Y; Compérat E; Rouprêt M; Cussenot O; Chen Y; Thompson EJ; Tannir NM; Weinstein JN; Valero V; Khayat D; Spano JP; Su X
Mol Oncol; 2015 Jan; 9(1):32-43. PubMed ID: 25126716
[TBL] [Abstract][Full Text] [Related]
23. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma.
Hakimi AA; Furberg H; Zabor EC; Jacobsen A; Schultz N; Ciriello G; Mikklineni N; Fiegoli B; Kim PH; Voss MH; Shen H; Laird PW; Sander C; Reuter VE; Motzer RJ; Hsieh JJ; Russo P
J Natl Cancer Inst; 2013 Dec; 105(24):1862-70. PubMed ID: 24285872
[TBL] [Abstract][Full Text] [Related]
24. Identification of 4-genes model in papillary renal cell tumor microenvironment based on comprehensive analysis.
Luo L; Zhou H; Su H
BMC Cancer; 2021 May; 21(1):553. PubMed ID: 33993869
[TBL] [Abstract][Full Text] [Related]
25. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
Pflueger D; Sboner A; Storz M; Roth J; Compérat E; Bruder E; Rubin MA; Schraml P; Moch H
Neoplasia; 2013 Nov; 15(11):1231-40. PubMed ID: 24339735
[TBL] [Abstract][Full Text] [Related]
26. Integral Analysis of the RNA Binding Protein-associated Prognostic Model for Renal Cell Carcinoma.
Qin X; Liu Z; Yan K; Fang Z; Fan Y
Int J Med Sci; 2021; 18(4):953-963. PubMed ID: 33456353
[TBL] [Abstract][Full Text] [Related]
27. MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.
Macher-Goeppinger S; Keith M; Endris V; Penzel R; Tagscherer KE; Pahernik S; Hohenfellner M; Gardner H; Grüllich C; Schirmacher P; Roth W
Oncotarget; 2017 Jan; 8(1):1046-1057. PubMed ID: 27894094
[TBL] [Abstract][Full Text] [Related]
28. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management.
Weng S; DiNatale RG; Silagy A; Mano R; Attalla K; Kashani M; Weiss K; Benfante NE; Winer AG; Coleman JA; Reuter VE; Russo P; Reznik E; Tickoo SK; Hakimi AA
Eur Urol; 2021 Apr; 79(4):468-477. PubMed ID: 33046271
[TBL] [Abstract][Full Text] [Related]
29. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
30. CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.
Chong TW; Goh FY; Sim MY; Huang HH; Thike AA; Lim WK; Teh BT; Tan PH
J Clin Pathol; 2015 Mar; 68(3):200-5. PubMed ID: 25477528
[TBL] [Abstract][Full Text] [Related]
31. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
[TBL] [Abstract][Full Text] [Related]
32. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
[TBL] [Abstract][Full Text] [Related]
33. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
[TBL] [Abstract][Full Text] [Related]
35. Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features.
Ito T; Pei J; Dulaimi E; Menges C; Abbosh PH; Smaldone MC; Chen DY; Greenberg RE; Kutikov A; Viterbo R; Uzzo RG; Testa JR
J Urol; 2016 Apr; 195(4 Pt 1):852-8. PubMed ID: 26602888
[TBL] [Abstract][Full Text] [Related]
36. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA profile in stage I clear cell renal cell carcinoma predicts progression to metastatic disease.
Moynihan MJ; Sullivan TB; Burks E; Schober J; Calabrese M; Fredrick A; Kalantzakos T; Warrick J; Canes D; Raman JD; Rieger-Christ K
Urol Oncol; 2020 Oct; 38(10):799.e11-799.e22. PubMed ID: 32534961
[TBL] [Abstract][Full Text] [Related]
38. Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients.
Fernandes FG; Silveira HCS; Júnior JNA; da Silveira RA; Zucca LE; Cárcano FM; Sanches AON; Neder L; Scapulatempo-Neto C; Serrano SV; Jonasch E; Reis RM; Evangelista AF
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668731
[TBL] [Abstract][Full Text] [Related]
39. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
[TBL] [Abstract][Full Text] [Related]
40. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
